Treatment of HBV-related liver disease in the dialysis population: reality and promises.
Fabrizi
F
F
Division of Nephrology and Dialysis, Ospedale Maggiore, Policlinico, IRCCS, Milano, Italy. ponticel@polic.cilea.it
Lunghi
G
G
Martin
P
P
D000998:Antiviral Agents / Q000627:therapeutic use; D016679:Genome, Viral; D006509:Hepatitis B / Q000150:complications* / Q000276:immunology / Q000628:therapy*; D006514:Hepatitis B Surface Antigens; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000628:therapy; D006801:Humans; D007121:Immunocompetence; D016898:Interferon-alpha / Q000009:adverse effects; D007674:Kidney Diseases / Q000150:complications* / Q000628:therapy; D019259:Lamivudine / Q000627:therapeutic use; D006435:Renal Dialysis; D014779:Virus Replication
D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D016898:Interferon-alpha; D019259:Lamivudine